Innovations in CRISPR advancing translational research

Over the past decade, CRISPR has proven itself a versatile and efficient tool for gene editing and modification. Its potential as a therapeutic agent is clear, but the current offerings lack the appropriate quality and consistency characteristics to realize this potential. To address this gap, Sigma-Aldrich^® is introducing the new PURedit^™ CRISPR reagents, specifically suited for preclinical and translational research.

PURedit^™ Cas9 is a novel variant that is designed with the key features of wild type and eSpCas9 combined – high activity and high on-target specificity. In addition, PURedit^™ synthetic sgRNAs are HPLC-purified to achieve the highest purity and quality. Their combination into an RNP complex aims to provide a highly efficient and consistent gene editing platform for therapeutic research, enabling researchers to move their therapies into the clinic faster.

Key learning objectives

• Explore the key requirements of CRISPR reagents for preclinical and translational research
• Understand performance and quality characteristics of gene editing reagents that make them ideal for preclinical research
• Learn how CRISPR reagents can be used in a variety of applications to provide enhanced-specificity without sacrificing cutting activity

Who should attend?

• Scientists from pharma, biotech, and academic institutions using gene editing for discovery or preclinical research.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.